A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Medical Investigation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2152/jmi.65.90PMID 29593202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer

  2015cited by this paper
• A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer: a report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901

  2014cited by this paper
• High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.

  2014cited by this paper
• Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809

  2013cited by this paper
• Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer.

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.

  2012cited by this paper
• Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study.

  2010cited by this paper
• Effect of Postoperative Adjuvant Chemotherapy with Tegafur-Uracil on Survival in Patients with Stage IA Non-small Cell Lung Cancer: An Exploratory Analysis from a Meta-Analysis of Six Randomized Controlled Trials

  2009cited by this paper
• Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

  2008cited by this paper
• Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

  2007cited by this paper
• Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes.

  2006cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.

  2004cited by this paper
• Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

  2004cited by this paper
• Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.

  1996cited by this paper
• Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.

  1993cited by this paper
• Continuous infusion chemotherapy: a critical review.

  1984cited by this paper

• Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301

  2021cites this paper
• A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer

  2020cites this paper
• 可切除Ⅲa/N2期非小细胞肺癌治疗模式探讨

  2019cites this paper
• MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

  2018cites this paper